Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
第3相
早期終了
NCT05223673
| 対象疾患 | Metastatic Colorectal Cancer |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Institut de Recherches Internationales Servier |
|---|
| ステータス | 早期終了 |
|---|
| 参加者数 | 7 名 |
|---|
| 介入（薬剤） | Futuximab/modotuximab, Trifluridine/Tipiracil, Trifluridine/Tipiracil |
|---|
| 開始日 | 2022年4月21日 |
|---|
| 完了日 | 2023年6月21日 |
|---|
| 結果公開日 | 2024年3月5日 |
|---|
概要
This is a randomized phase III study with a safety lead-in part in patients with KRAS/ NRAS and BRAF Wild Type metastatic colorectal cancer who have previously received treatment with oxaliplatin, irinotecan, fluoropyrimidines, anti-VEGF agents and anti-EGFR antibodies. The main objective of the safety lead-in part is to assess safety and tolerability of futuximab/modotuximab in combination with trifluridine/tipiracil. The primary objective of the phase III part is to compare Overall Survival of futuximab/modotuximab in combination with trifluridine/tipiracil vs trifluridine/tipiracil monotherapy in patients with tumours that are KRAS/NRAS and BRAF wild-type (WT).
Incidence of Dose-limiting Toxicities (DLTs) (Safety Lead-In Part)
End of cycle 1 (Each cycle is up to 28 days) · dose-limiting toxicities (DLTs)
| Futuximab/Modotuximab Combined With Trifluridine/Tipiracil (Safety Lead-In and Phase III Parts) | 0 dose-limiting toxicities (DLTs) |
|---|
Overall Survival (OS) (In Double Negative, KRAS/NRAS and BRAF Wild Type Patients) (Phase III Part)
up to 4 years 9 months
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。